Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.

Front Oncol · 2020 · PMC7758444 · PMID 33363040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

Several studies revealed that patients with coexisting TP53 mutations treated with EGFR-TKIs showed a trend toward lower ORR, shorter PFS, and OS compared to patients with wild-type TP53 that did not reach statistical significance ( 28 – 31 , 68 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.